Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 studyAkito Hata, Nobuyuki Yamamoto, Hideaki Okada et al.|The Lancet Oncology|2025Cited by 5